Adjunctive therapy with perampanel reduces seizures in patients with drug-resistant primary generalized tonic–clonic seizures, a recent trial shows. 162 patients on antiepileptic drugs were randomly allocated to also receive either perampanel or a placebo during a 4-week titration period, followed by a 13-week maintenance period. Seizure frequency per 28 days was reduced by 76.5% in patients who received perampanel, but only by 38.4% in patients who received the placebo. 30.9% of patients who received parempanel and 12.3% of patients who received the placebo became free of seizures during maintenance.
References
French, J. A. et al. Perampanel for tonic–clonic seizures in idiopathic epilepsy: a randomized trial. Neurology 10.1212/WNL.0000000000001930
Rights and permissions
About this article
Cite this article
Perampanel success in primary generalized seizures. Nat Rev Neurol 11, 547 (2015). https://doi.org/10.1038/nrneurol.2015.163
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.163